Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Benign or Malignant Pancreatic Diseases Clinical Trial

Official title:

Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04055571
• Other study ID #: 036.HPB.2018.R
• Status: Recruiting
• Start date: March 5, 2019
• Est. completion date: January 30, 2025

Study information

• Verified date: March 2024
• Source: Methodist Health System
• Contact: Crystee Cooper, DHEd
• Phone: 214-947-1280
• Email: CrysteeCooper[@]mhd.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will be a retrospective chart review of patients who have been diagnosed with the benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either investigator's patients or through a national database. Data will be analyzed primarily by the study conductors.

Description:

It is reported in the literature that the treatment of any pancreatic disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The investigator's goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality, and morbidity.

The main aim of this study is to evaluate and compare the outcomes from the investigator's decisions on multiple treatments of benign or malignant pancreatic diseases.There is a need to understand and improve the current diagnosis and treatment algorithm for pancreatic pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.

All past patients who were treated for a particular benign or malignant pancreatic disease process under evaluation from 2005 to present will be included in this study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: January 30, 2025
• Est. primary completion date: January 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • All patients diagnosed and treated for pancreatic diseases, benign or malignant from 2005 to present

• Age =18 years

Exclusion Criteria:

• • Patients that are not diagnosed with or treated for pancreatic diseases

• Age < 18 years

Related Conditions & MeSH terms

• Benign or Malignant Pancreatic Diseases
• Pancreatic Diseases

Locations

Country	Name	City	State
United States	Trinity Surgical Consultants, Methodist Richardson Medical Center	Richardson	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Methodist Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Number of patients who have been diagnosed with benign or malignant pancreatic disease	2005 to 2019